BNIP3L is a new prognostic biomarker for melanoma patients (Kazimierczak et al., 2020) and is related to the development and metastasis of hepatocellular carcinoma (HCC) and colon cancer (Chen et al., 2020). This evidence concerns the gene BNIP3L and melanoma.